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SH3 domains regulate many normal and pathological cellular processes by guiding specific protein interactions. Studies
on binding of HIV-1 Nef to the SH3 domain of the Hck tyrosine kinase have indicated an important role for the SH3 RT-loop
region in ligand binding. Here we have tested the potential of artificial Hck-derived SH3 domains carrying tailored RT-loops
providing high affinity for Nef as intracellular inhibitors of Nef. These artificial SH3 domains efficiently associated with Nef
in cells and thereby potently inhibited SH3-dependent Nef functions, such as association with p21-activated kinase-2 and
induction of the transcription factor NFAT. On the other hand, biochemical and functional data indicated that the Nef-targeted
SH3 domains were not prone to compete with normal SH3-mediated processes. Thus, RT-loop-modified SH3 domains
represent a novel approach for selectively interfering with cellular signaling events, which could be exploited in research as
well as in therapeutic applications. © 2001 Academic Press
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HINTRODUCTION
Many aspects of cell behavior are controlled by dy-
namic and ordered proximity of cellular proteins. During
evolution several different types of protein interaction
domains specialized in mediating such regulated and
specific protein–protein communication have emerged.
The SH3 domain was first identified as a region of ho-
mology among the Src family tyrosine kinases (Cohen et
al., 1995; Dalgarno et al., 1997; Sudol, 1998). Thereafter
SH3 domains have been noticed in a large number of
proteins, and a total of 63 SH3 domains were found in the
fruit fly genome (Rubin et al., 2000), while more than 200
human proteins with SH3 domains can currently be
found from the SwissProt database (using SMART;
Schultz et al., 1998). Because SH3 domains often serve
functions in the regulation of cell growth and differenti-
ation they are intimately involved in the pathogenesis of
diseases such as cancer. In addition, a number of mi-
crobial pathogens, such as HIV, exploit SH3-mediated
processes as a part of their life cycle (Bliska, 1996;
Saksela et al., 1995).
SH3 domains are small (55–70 amino acids) modular
protein units, which mediate inter- and intramolecular
protein interactions by binding to ligands that contain a
region with a secondary structure known as the polypro-
line type II (PPII) helix (Kuriyan and Cowburn, 1997;
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152Mayer and Gupta, 1998). Sequence variation in the PPII
helix region of the ligand (the “PxxP motif”) can influence
the specificity in SH3/ligand complex formation. How-
ever, work on HIV-1 Nef/SH3 interactions has demon-
strated that a major contribution for binding affinity and
specificity is provided by molecular contacts outside the
SH3/PxxP interface (Lee et al., 1995, 1996). Specifically,
an SH3 structure known as the RT-loop, which is highly
divergent among the otherwise similar SH3 domains,
can play a key role in determining the ligand binding
properties of individual SH3 domains.
In a previous study (Hiipakka et al., 1999) we have
exploited the latter concept to engineer artificial SH3
domains with novel specificities and high binding affini-
ties. This was done by using phage display to select
clones from large libraries of SH3 domains in which six
nonconserved residues in the RT-loop of Hck-SH3 had
been substituted by random amino acid combinations.
Using this approach we have developed a panel of arti-
ficial SH3 domains (termed RRT-SH3 for randomized RT-
loop) that bind to HIV-1 Nef with unnaturally high binding
affinities (K D values in the order of 10
28 to 1029 M com-
pared to 1023 to 1026 M for most natural SH3 interactions;
iipakka et al., 1999).
Inspired by experiments in which recombinant single-
chain antibodies (ScFv’s) have been expressed in mam-
malian cells to inhibit or relocalize cellular target pro-
teins (Chames and Baty, 2000; Hudson, 1999), in this
study we have examined the potential of our Nef-tar-
geted RRT-SH3 domains to serve as intracellular inhibi-
tors of Nef. We show that the high binding affinity of
these artificial SH3 domains in vitro is indeed reflected
s
s
t
153ARTIFICIAL SH3 DOMAINS INHIBIT Nef FUNCTIONby efficient complex formation with Nef expressed in
cells and that this binding results in potent inhibition of
SH3-dependent cellular functions of Nef. Importantly, the
majority of cellular proteins that coprecipitated with na-
tive Hck-SH3 did not associate with the Nef-targeted
RRT-SH3 domains. These data highlight the importance
of the RT-loop in SH3 ligand recognition and demonstrate
the feasibility of this novel approach for interfering with
SH3-mediated intracellular processes.
RESULTS
RRT-SH3s associate efficiently with Nef in
cotransfected cells
Our previous studies have demonstrated a critical role
for the SH3 domain RT-loop region in ligand binding (Lee
et al., 1995, 1996). To exploit this concept experimentally
we have developed artificial Hck-derived SH3 domains
(RRT-SH3s) that can bind their target proteins more se-
lectively and with higher affinities than natural SH3 do-
mains (Hiipakka et al., 1999). In simple biochemical test
ystems RRT-SH3s engineered to bind to HIV-1 Nef
howed affinities with dissociation constants (K D) lower
han 1028 M. Thus, the strength of these interactions is in
the range characteristic of affinity of antibody–antigen
binding rather than SH3-mediated interactions (Hiipakka
et al., 1999).
This strong affinity led us to examine if our tailored
SH3 domains could serve as specific inhibitors of intra-
cellular functions of Nef. For this purpose five RRT-SH3s
targeted for Nef were subcloned into a mammalian ex-
pression vector (Fig. 1). To facilitate detection and puri-
fication they were expressed as GST-SH3 fusion pro-
teins, as an N-terminal GST moiety had previously been
found not to affect their in vitro binding properties
(Hiipakka et al., 1999). Translation of this fusion protein
was engineered to start from a 14-amino-acid myristoy-
lated N-terminal sequence of v-Src placed in front of the
GST reading frame. This was done to enhance localiza-
tion of the GST-SH3 domains on cellular membranes
(where most of myristoylated Nef protein resides), but is
not expected to exclude this fusion protein from other
subcellular compartments. In addition, an HA-epitope tag
was appended to the carboxy termini of these con-
structs. A similarly designed plasmid expressing the
Hck-SH3 domain was also constructed. Although much
weaker than RRT-SH3/Nef binding, the interaction be-
tween Hck-SH3 and Nef is among the tightest of the
known natural SH3-mediated protein interactions (K D
value 0.2 mM; Lee et al., 1995). As a negative control, a
similar expression vector for GST was also made.
To examine the ability of these GST-SH3 fusion pro-
teins to bind to Nef in mammalian cells they were co-
transfected with Nef into 293T cells. Forty-eight hours
after transfection the cells were lysed, and the GST or
GST-SH3 proteins were captured by glutathione Sepha-rose beads. After extensive washing the proteins that
remained associated with the beads were examined by
SDS–PAGE and Western blotting. Small aliquots of the
lysates were removed before the glutathione affinity se-
lection step and used to examine the expression levels
of Nef and GST-SH3 (or empty GST) proteins in the
transfected cells.
As shown in Fig. 2A, equal levels of Nef were present
in lysates of cells cotransfected with the vectors for GST
or GST-SH3, and the latter proteins were also expressed
in similar amounts. Accordingly, the amounts of the GST
and GST-SH3 proteins (Hck, A1, A2, and B6) captured
from these lysates using the glutathione Sepharose
beads were also roughly similar (Fig. 2B). By contrast, the
amounts of coprecipitated Nef varied widely. As ex-
pected, the GST protein without an SH3 domain did not
precipitate any Nef. In agreement with the known affinity
of the Hck-SH3 domain for Nef, readily detectable
amounts of Nef remained bound to the beads with GST-
Hck-SH3. However, the RRT-SH3 domains (A1, A2, and
B6) were significantly more efficient than Hck-SH3 in
associating with Nef.
Although the Western blotting signals specific for the
GST-SH3 and Nef proteins detected in parallel using
anti-HA and anti-Nef antibodies, respectively, may not be
directly comparable, the similar intensities of these sig-
nals suggested that the RRT-SH3 domains remained
bound to Nef at close to an equimolar ratio. Moreover,
FIG. 1. A schematic representation of the myristoylated GST-SH3
proteins. (A) Amino acid residue numbers of the v-Src/GST/SH3/HA-tag
fusion protein are shown under the construct. The numbers on top of
the construct at the borders of the SH3 domain correspond to the
amino acid numbering of human Hck kinase. Positions of the bulky
hydrophobic SH3 amino acids that form the docking surface for the
PxxP motif of Nef are also indicated. The six nonconserved SH3
residues located in the tip of the RT-loop, which constitute the engi-
neered region in the RRT-SH3 domains, are depicted by a black bar. (B)
RT-loop sequences and Nef binding properties of the SH3 domains
tested. Affinity data are from Hiipakka et al. (1999).when the amount of Nef remaining in the lysates after
this GST-SH3 pull-down step was examined, only traces
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the RRT-SH3 domains, whereas in the lysate of the Hck-
SH3-expressing cells the amount of Nef was only mod-
estly reduced compared to the original lysate (data not
shown). As expected based on our previous in vitro data
(Hiipakka et al., 1999), an SH3 binding-defective Nef
mutant unable to bind Hck-SH3 because of alanine sub-
stitutions in place of both of the PxxP-motif-defining pro-
line residues (Manninen et al., 1998) failed to associate
with the Nef-targeted RRT-SH3 domains in cotransfected
cells (Fig. 2, right panels, and data not shown).
RRT-SH3 domains bind poorly to normal cellular
ligands of Hck-SH3
When considering the use of these modified SH3 do-
mains as intracellular inhibitors, it would be desirable
that, besides the strong binding to their specific target,
they would show minimal binding to the natural sub-
strates of their parental SH3 domains. Because of the
intimate involvement of the RT-loop in SH3 ligand selec-
tion, changes in the SH3 RT-loop region that increase the
affinity for a particular ligand would be expected to con-
FIG. 2. Efficient intracellular engagement of Nef by RRT-SH3 do-
ains. Lysates of 293T cells transfected with vectors for Nef and
ifferent GST-SH3 proteins (or plain GST) were examined by immuno-
lotting using anti-Nef and anti-HA or anti-GST antibodies either di-
ectly (A, total lysates) or after binding to glutathione Sepharose beads
B, beads). In panels on the left, wild-type Nef was transfected in all
ases, whereas in panels on the right wild-type or an SH3 binding-
eficient mutant Nef was used as indicated.versely decrease binding to other ligands. Thus, we were
hopeful that our Nef-targeted RRT-SH3 domains wouldbe deficient in binding to natural partners of Hck. To test
this hypothesis we compared the patterns of proteins
coprecipitating from cell extracts with wild-type Hck-SH3
or its RRT-SH3 derivatives.
Because Hck is expressed mainly in cells of the my-
eloid lineage, we used the cell lines U937 and K562 as
sources for endogenous Hck-SH3 binding proteins.
Since many SH3 ligand proteins are components of cel-
lular signaling cascades, and become tyrosine phos-
phorylated upon activation of these cascades, we
treated the cell lines with the tyrosine phosphatase in-
hibitor sodium orthovanadate in order to allow sensitive
detection of such proteins by anti-phosphotyrosine West-
ern blotting. Equal fractions of these lysates were incu-
bated with recombinant GST or GST-SH3 proteins immo-
bilized to glutathione Sepharose beads. After washing of
the beads the bound proteins were separated by SDS–
PAGE and subjected to anti-phosphotyrosine immuno-
blotting (Fig. 3).
Several proteins in the 40- to 70-kDa size range that
were strongly reactive with the anti-phosphotyrosine an-
tibody could be precipitated by the SH3 domains. Some
of these appeared to be common to both cell lines (pp54
and pp67), whereas some were preferentially expressed
either in U937 (pp44, pp49, and pp51) or in K562 (pp52,
pp58, and pp64) cells. This precipitation was SH3-spe-
cific, since no anti-phosphotyrosine signal was derived
FIG. 3. RRT-SH3s bind poorly to normal cellular ligands of Hck-SH3.
K562 and U937 cells were stimulated with pervanadate before lysis.
These lysates were incubated with the indicated recombinant GST-SH3
proteins bound to glutathione Sepharose beads. The associated pro-
teins were resolved by electrophoresis and analyzed by immuno-
blotting with an anti-phosphotyrosine antibody.
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control). With the exception of two prominent 58- and
60-kDa phosphotyrosine-containing proteins (pp58 and
pp60) that were precipitated by all the SH3 domains from
U937 and K562 cell lines, respectively, most of these
phosphoproteins were either preferentially or exclusively
associated with wild-type Hck-SH3. For example, in both
cell lines a major 67-kDa (pp67) tyrosine-phosphorylated
protein was seen associated with Hck-SH3, whereas it
was recognized much less well by the RRT-SH3 domains
A1 and C1, poorly by B6, and not at all by A2. Of the
54/52-kDa doublet precipitated by Hck-SH3 from K562
cells only pp54 was faintly associated with certain RRT-
SH3s, whereas pp52 was not bound at all. Similarly, the
44-kDa protein (pp44) that gave rise to an intense anti-
phosphotyrosine signal in the lane containing Hck-SH3-
bound proteins from U937 cells was only weakly asso-
ciated with C1, but was not precipitated at all by the other
RRT-SH3 domains. Although the relative intensities of
these K562- and U937-derived phosphoproteins varied
slightly between the experiments, similar patterns of
anti-phosphotyrosine-reactive bands as shown in Fig. 3
were reproducibly observed using independent prepara-
tions of GST-SH3 proteins as well as different batches of
orthovanadate-stimulated cell lysates (data not shown).
Thus, as predicted, the endogenous cellular target
proteins of Hck-SH3 strongly depended in their binding
on the six RT-loop residues naturally present in wild-type
Hck and therefore bound much less well to the artificial
RRT-SH3 domains where these residues had been
changed in order to generate strong affinity for Nef.
RRT-SH3s inhibit association of Nef with PAK2
Some of the pathogenic effect of HIV-1 Nef is thought
to be mediated via its association with a cellular serine
kinase previously known as Nef-associated kinase (NAK;
Sawai et al., 1994) and recently identified as p21-acti-
vated kinase 2 (PAK2; Renkema et al., 1999). Although
PAK2 itself does not contain an SH3 domain, association
of Nef with PAK2 is dependent on the SH3 binding
capacity of Nef (Manninen et al., 1998), presumably be-
cause SH3-containing adaptor proteins are required to
stabilize this complex. Efficient autophosphorylation of
PAK2 bound to Nef provides an easy and sensitive read-
out for the ability of Nef to associate with this kinase and
hence for the capability of coexpressed RRT-SH3 do-
mains to prevent this interaction. To maximally induce
the autokinase activity of PAK2 a constitutively active
form of the p21 GTPase V12cdc42 was also cotrans-
fected.
After immunoprecipitation of Nef and associated cel-
lular proteins from the transfected cells these immuno-
complexes were subjected to an in vitro kinase assay. As
shown in Fig. 4, in the absence of transfected SH3
domains an intense Nef-associated PAK2 signal wasdetected by IVKA. While coexpression of Hck-SH3 re-
sulted in a partial reduction in Nef-associated PAK2 ac-
tivity, the cotransfected RRT-SH3 domains (A1, A2, B4, B6,
and C1) almost completely blocked formation of the Nef/
PAK2 complex. When the expression levels of Nef in cells
transfected with or without an SH3 vector were exam-
ined by Western blotting analysis of either the unselected
lysates or of the anti-Nef immunoprecipitates used for
IVKA very similar results were obtained (data not shown).
Therefore, the loss of PAK2 signal in the anti-Nef immu-
noprecipitates from RRT-SH3-expressing cells was not
due to a failure of the anti-Nef antibody to detect Nef in
complex with the RRT-SH3 domains. Thus, in agreement
with the RRT-SH3/Nef coprecipitation studies (Fig. 2),
these data indicated that the RRT-SH3 domains could
effectively prevent the SH3-dependent association of Nef
with PAK2, an interaction that is believed to be important
for the pathogenicity of Nef (Sawai et al., 1996;
Wiskerchen and Cheng-Mayer, 1996).
RRT-SH3s inhibit Nef-induced activation of NFAT
We have recently shown (Manninen et al., 2000) that
Nef can activate nuclear translocation of the transcrip-
tion factor NFAT (nuclear factor of activated T cells; Rao
et al., 1997). Thereby Nef can cooperate with the MAPK
(mitogen-activated protein kinase)-signaling pathway in
inducing gene expression via the ARRE2 element (anti-
gen receptor responsive element of the IL-2 gene; Rao et
al., 1997). ARRE2 is a classic example of a composite
NFAT/AP-1 (activator protein-1) binding site, which can
be found in a number of genes involved in T cell activa-
tion (Latinis et al., 1997; Shaw et al., 1988). Like associ-
ation with PAK2, activation of NFAT-dependent transcrip-
tion also correlates with the capacity of Nef for SH3
binding (Manninen et al., 2001).
To examine the potential of the RRT-SH3 domains to
FIG. 4. RRT-SH3s inhibit PAK2 activity associated with Nef. 293T cells
were transfected with Nef and SH3 expression plasmids and a domi-
nant active V12cdc42. Equal amounts of protein lysates normalized for
their protein concentration were subjected to an anti-Nef immunopre-
cipitation, followed by an in vitro kinase assay.inhibit NFAT activation by Nef, Jurkat T cells were co-
transfected with Nef and an ARRE2-driven luciferase
156 HIIPAKKA ET AL.reporter plasmid together with different RRT-SH3 vectors
(A1, A2, B4, B6, and C1), Hck-SH3 or the control GST
vector. In addition, an elongation factor promoter-driven
b-galactosidase expression vector was also cotrans-
fected to confirm uniform transfection efficiency. Twenty
hours after transfection the cells were stimulated with
phorbol 12-myristate 13-acetate (PMA) for 4 h (to activate
MAPK signaling), after which they were lysed and exam-
ined for luciferase and b-galactosidase activities.
When Nef was expressed together with the control
GST vector NFAT activity in PMA-treated cells was in-
creased approximately 30-fold, compared to similarly
treated cells that did not express Nef (Fig. 5A). All of the
RRT-SH3 domains tested strongly reduced the NFAT ac-
FIG. 5. RRT-SH3s inhibit the Nef-induced NFAT activation. (A) Jurkat
cells were transfected with the NFAT luciferase plasmid and different
SH3 expression vectors along with Nef (dark bars) or a control vector
(light bar). Twenty hours later the transfected cells were stimulated with
PMA, followed by luciferase activity measurement 4 h later. The mean
luciferase activities from three independent transfections are shown.
Interassay variation is indicated by standard error bars. (B) Increasing
amounts of Hck-SH3 or B6 along with constant amounts of Nef and the
NFAT luciferase reporter were transfected into Jurkat cells and pro-
cessed as in A. The mean luciferase activities from four independent
transfections are shown plotted relative to mean values from control
cells that did not receive any SH3 plasmid (5100%). Interassay varia-
tion is indicated by standard error bars. (C) Increasing amounts of
Hck-SH3 or B6 expression vector together with the NFAT luciferase
plasmid were transfected into Jurkat cells. Twenty hours after transfec-
tion the cells were stimulated with anti-CD3 and anti-CD28 antibodies
for 5 h followed by luciferase activity measurement. The data are
presented as in B and also represent mean values of four independent
experiments. Interassay variation is indicated by standard error bars.tivation induced by Nef 1 PMA, resulting in the lucif-
erase activities down to 10% of the control cells. We werefirst surprised to notice that despite being much less
efficient in associating with Nef (Fig. 2) and in displacing
Nef-bound PAK2 (Fig. 4), Hck-SH3 was as potent as the
RRT-SH3 proteins in inhibiting Nef-induced NFAT activa-
tion. Therefore, we compared the potency of Hck-SH3
and B6-SH3 in this assay by titrating the amount of SH3
vector transfected together with a constant amount of
Nef and the reporter (Fig. 5B). While confirming the dose-
dependent nature of NFAT inhibition, this experiment still
indicated that in comparison with B6-SH3, Hck-SH3 was
at least as strong as or probably a stronger inhibitor of
Nef-induced NFAT activation.
Although Nef is necessary for activation of NFAT-de-
pendent gene expression in PMA-treated Jurkat cells, it
is not sufficient and many cellular signal transducing
factors contribute to this increase of ARRE2-mediated
transcription. Since some of these factors could be nat-
ural targets of Hck-SH3, we performed another dose–
response experiment in which we compared the potency
of Hck-SH3 and B6-SH3 as inhibitors of Nef-independent
NFAT activation triggered via T cell receptor ligation by
anti-CD3 and anti-CD28 antibodies. As shown in Fig. 5C,
transfection of B6, even in amounts that caused maximal
inhibition of Nef 1 PMA-stimulated NFAT activity, did not
result in significant reduction of NFAT activity stimulated
by anti-CD3/anti-CD28 antibodies. By contrast, Hck-SH3
also proved to be a relatively efficient inhibitor in this
Nef-independent NFAT activation assay, resulting in 50%
inhibition even when relatively small amounts of the
Hck-SH3 vector were transfected.
Thus, we concluded that inhibition of Nef-induced
NFAT activation by B6 was specifically caused by neu-
tralization of Nef function and that the unexpected po-
tency of wild-type Hck-SH3 in this assay was due to
additional inhibition of parallel signaling events that sup-
port ARRE2-mediated gene expression upon activation
of Jurkat cells. These results are in agreement with the
data shown in Fig. 3, indicating that the increased affinity
of the RRT-SH3 domains for Nef is associated with de-
creased binding to cellular proteins targeted by wild-type
Hck-SH3.
RRT-SH3s do not block an SH3-independent function
of Nef
Downregulation of cell surface expression of the CD4
molecule is a well-characterized cellular function of Nef
and involves Nef-mediated coupling of CD4 to the cellu-
lar endocytic machinery (Aiken et al., 1994). In contrast to
the two earlier discussed functions of Nef, CD4 down-
regulation is not dependent on SH3 binding by Nef (Sak-
sela et al., 1995). However, because engagement of the
SH3 binding surface of Nef by an RRT-SH3 domain could
affect the functionality of Nef in a more global manner,
we chose also to examine the effects of RRT-SH3 ex-
pression on Nef-induced CD4 downregulation.
S
1
R
f
m
f
e
a
t
w
N
b
g
i
b
p
t
w
t
s
W
t
t
v
n
c
i
w
a
i
b
d
c
t
r
a
(
u
e
t
157ARTIFICIAL SH3 DOMAINS INHIBIT Nef FUNCTIONTo address this question 293T cells were transfected
with plasmids expressing human CD4, green fluorescent
protein (GFP), Nef, or an empty control vector, and RRT-
SH3-B6 or the corresponding GST-only control vector.
Forty-eight hours after transfection the cells were col-
lected and analyzed by flow cytometry. Figure 6 shows
histograms of CD4-specific fluorescence among the
GFP-expressing cells (i.e., positively transfected cells) in
cultures transfected with Nef, with or without B6 and in
control cells (no Nef transfected).
Although the ratio of Nef vs B6-SH3 transfected was
the same that gave maximal inhibition of Nef-mediated
NFAT activation, the ability of Nef to induce downregu-
lation was not significantly decreased. Thus, in agree-
ment with the earlier mutagenesis data showing that
SH3 binding is not involved in CD4 downregulation by
Nef (Saksela et al., 1995), occupancy of the SH3 binding
surface of Nef by a high-affinity RRT-SH3 domain did not
interfere with this function.
DISCUSSION
This study demonstrates the utility of artificial SH3
domains as inhibitors of cellular functions of the HIV-1
pathogenicity factor Nef. Recently there has been signif-
icant interest as well as success in using intracellular
expression of single-chain antibodies (intrabodies) for
interfering with the functions of proteins involved in the
pathogenesis of cancer (Hudson, 1999) and HIV infection
(Rondon and Marasco, 1997), and this approach has
been hailed as a potential tool in gene therapy for these
diseases. Because of the solubility problems often asso-
ciated with single-chain antibodies (Hudson, 1998; Ja¨ger
and Plu¨ckthun, 1999) as well as the potential immuno-
FIG. 6. RRT-SH3 domains do not interfere with Nef-induced down-
egulation of CD4. FACScan data illustrating CD4-specific fluorescence
mong GFP-expressing 293T cells transfected with Nef in the presence
dotted line) or the absence (continuous line) of B6-SH3 are shown as
nshaded histograms, and CD4 expression of the control cells not
xpressing Nef or B6 is shown as a shaded histogram. A representa-
ive data set of three similar experiments is shown.genicity of the linker peptides included in these, the use
of inhibitory RRT-SH3 domains, when applicable, couldbe an advantageous alternative. It cannot be ruled out,
however, that the amino acid changes in the RT-loops of
RRT-SH3 proteins could in some cases cause similar
complications.
We found that Hck-derived RRT-SH3 domains targeted
for high-affinity (K Ds in the range of 10
28 to 1029 M;
Hiipakka et al., 1999) binding to Nef could efficiently
inhibit the two SH3-dependent functions of Nef, namely,
recruitment of activated PAK2 kinase and activation of
NFAT-dependent gene expression. By contrast, down-
regulation of cell surface expression of CD4, which is an
exception among the cellular functions of Nef in being
independent of SH3 binding, was not affected. Thus, this
trans-inhibition strategy correlated well with previous
studies in which the functionality of Nef has been inhib-
ited by site-directed mutagenesis (Goldsmith et al., 1995;
aksela et al., 1995; Wiskerchen and Cheng-Mayer,
996). Although not observed here, it is possible that
RT-SH3 binding could also block SH3-independent
unctions of their target proteins by noncompetitive
echanisms, e.g., by inducing changes in protein con-
ormation, subcellular localization, or stability. In fact, it is
asy to envision strategies to modify the RRT-SH3 by
ttaching additional functional motifs in order to provide
hem with such noncompetitive inhibitory potential
here this would be considered beneficial.
Besides demonstrating the inhibitory potential of the
ef-targeted RRT-SH3 proteins, this study also provides
iochemical and functional support for the idea that the
ain in affinity for Nef caused by the six artificial residues
ntroduced into the RT-loop of Hck-SH3 is accompanied
y a reduced binding to its normal cellular targets. Ex-
ression of Hck-SH3 was found to inhibit T cell receptor-
riggered activation of NFAT-dependent gene expression,
hereas a Nef-targeted RRT-SH3 derivative did not in-
erfere with this normal cellular response and instead
pecifically blocked only Nef-induced NFAT activation.
hile poor binding of the Nef-targeted RRT-SH3 domains
o the natural ligands of Hck is obviously important for
heir use as specific intracellular inhibitors, this obser-
ation also highlights the critical role of the RT-loop in
atural SH3-mediated cellular interactions.
The interface between the proline-rich SH3 binding
onsensus motif and its docking surface on the SH3 fold
s relatively similar in different SH3/ligand complexes,
hich limits the maximal specificity that can be gener-
ted by modifications in the RT-loop. Thus, if expressed
n sufficiently high amounts RRT-SH3 domains could also
ind and inhibit random cellular SH3 binding proteins
espite the mismatch of their RT-loops. However, be-
ause of the magnitude of the contribution by the RT-loop
o SH3 binding affinity (Hiipakka et al., 1999; Lee et al.,
1995), it does not seem difficult to ensure a suitable level
of RRT-SH3 expression, which would result in strong
specific inhibition but minimal interference with other
SH3-mediated cellular processes.
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sion of SH3 domains with tailored RT-loops can be used
as a novel approach for inhibition of intracellular signal-
ing events. This strategy might also be extended to other
protein interaction domains where specificity/affinity de-
terminants similar to the SH3 domain RT-loop are known.
Such inhibitors should prove useful in deciphering the
complex cellular signaling cascades and could provide
novel tools for gene therapy as well as help to guide
development of small molecular compounds with similar
inhibitory properties.
MATERIALS AND METHODS
Cell cultures and transfections
293T, Jurkat (JE-6), U937, and K562 cells were obtained
from ATCC and were cultured using standard proce-
dures. 293T cells were transfected by Lipofectamine
reagent (Life Technologies) and JE-6 cells by DMRIE-C
transfection reagent as suggested by the supplier (Life
Technologies).
Reagents
The expression vector for dominant active cdc42
(V12cdc42) and the pEBB and pEBB vector that contained
a v-Src N-terminal myristoyl tail and a C-terminal HA-
epitope tag (pEBB-myr-HA) were kindly provided by Dr.
Bruce Mayer (University of Connecticut, Farmington). The
NL4-3 Nef allele R71 (Saksela et al., 1995) was cloned
into the pEBB expression vector, the SH3 domains of
Hck-SH3, clones A1, A2, B4, B6, and C1 (Hiipakka et al.,
1999) were subcloned as GST fusions into the pEBB-
myr-HA vector. The vector for SV40-CD4 was from Dr.
Ned Landau (Salk Institute, La Jolla).
The Nef mouse monoclonal antibodies (2F2, 2A3, 3A2,
6.2, 2H12, 3E6, and 3F2.1) were provided by Vladimir
Ovod from our institute, and the sheep polyclonal Nef
antibody by Dr. Mark Harris (University of Leeds, UK).
The anti-HA antibody was purchased from BabCO
(Berkeley, CA), the anti-phosphotyrosine antibody PY99
from Santa Cruz (Santa Cruz, CA), anti-CD3 (HIT3a) and
the phycoerythrin-conjugated anti-CD4 antibodies from
Pharmingen, anti-CD28 monoclonal antibody from CLB
(Amsterdam, Netherlands), biotinylated anti-mouse IgG
from DAKO, biotinylated streptavidin–horseradish perox-
idase conjugate from Amersham Pharmacia Biotech, and
anti-goat/sheep IgG-AP GT34 conjugate from Sigma.
Expression and purification of GST and GST-SH3 were
carried out as previously described (Hiipakka et al.,
1999).
Detection of transfected proteins
293T cells were harvested 48 h after transfection,
washed with standard phosphate-buffered saline (PBS),
and lysed in in vitro kinase assay lysis buffer (IVKA lysisbuffer; 50 mM HEPES, pH 7.4, 150 mM NaCl, 10% glyc-
erol, 1% Triton X-100, 1 mM EGTA, 1.5 mM MgCl2, 10 mM
aF, 1 mM Na-orthovanadate 1 mM phenylmethylsulfo-
yl fluoride (PMSF), and 10 mg/ml aprotinin). Lysates (1
mg of total cellular protein) were incubated with gluta-
thione Sepharose 4B beads (Amersham Pharmacia Bio-
tech) for 4 h at 4°C and washed with IVKA lysis buffer.
The proteins were separated by SDS–PAGE followed by
immunoblotting done as described previously (Manninen
et al., 1998).
For IVKA the monoclonal 2F2 Nef antibody was incu-
bated with 500 mg of total cellular protein and protein
G–Sepharose beads (Sigma) for 4 h at 4°C. After wash-
ing three times with IVKA lysis buffer and twice with
kinase assay buffer (50 mM HEPES, pH 7.4, and 5 mM
MgCl2) [g-
32P]ATP (2.5 mCi; Amersham Pharmacia Bio-
tech) was added to the immunoprecipitates followed by
a 30-min incubation at 37°C. The beads were washed
with ice-cold PBS and boiled in Laemmli sample buffer,
followed by SDS–PAGE and exposure on BioMax MR film
(Kodak).
The reagents and protocols used for the luciferase
assays were exactly as described previously (Manninen
et al., 2000).
For the CD4 downregulation assay 293T cells were
cotransfected with human CD4 and GFP alone or to-
gether with Nef R71 and B6. Forty-eight hours after trans-
fection the cells were harvested and washed with PBS 1
0.1% BSA and stained with PE-conjugated anti-human
CD4 (dilution 1:10) for 30 min. After two washes with
PBS 1 0.1% BSA the stained cells were suspended in
PBS 1 0.5 mM EDTA. The CD4 surface expression
among the GFP-positive cells was examined using FAC-
Scan (Becton–Dickinson).
K562 and U937 cells were stimulated by pervanadate
as described in Jin et al. (1999). The lysates were prein-
cubated with recombinant GST protein (10 mg/mg total
protein) at 4°C for 2 h, followed by capture on glutathione
Sepharose 4B beads. These precleared lysates were
split into aliquots corresponding to 500 mg of total cel-
lular protein and incubated for 2 h at 4°C with beads
coated with 8 mg of GST or GST-SH3. The beads were
washed three times with Nonidet P-40 lysis buffer (1%
Nonidet P-40, 150 mM NaCl, 20 mM Tris–Cl, pH 7.4, 0.5%
sodium deoxycholate, 50 mM NaF, 1 mM PMSF, and 10
mg/ml aprotinin) and once with PBS and boiled in
Laemmli sample buffer, followed by SDS–PAGE and anti-
phosphotyrosine immunoblotting.
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